BOULDER, Colo., April 27, 2015 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2015 and hold a conference call to discuss those results on Monday, May 4, 2015. Ron Squarer, Chief Executive Officer will lead the call.

Date:

Monday, May 4, 2015

Time:

9:00 a.m. Eastern Time

Toll-Free:

(844) 464-3927

Toll:

(765) 507-2598

Pass Code:

5249676

Webcast, including Replay and Conference Call Slides: http://edge.media-server.com/m/p/8tsxszuw/lan/en

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six Phase 3 studies are currently enrolling patients. These programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia Haugeto


Array BioPharma Inc.


(303) 386-1193


thaugeto@arraybiopharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2015-on-may-4-2015-300072840.html

SOURCE Array BioPharma Inc.

distributed by